PTK787/ZK 222584 (1-[4-chloroanilino]-4-[4-pyridylmethyl]phthalazine succinate) is a potent
inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, active in …

Since the late 1980s, mutations in the RAS genes have been recognized as major oncogenes
with a high occurrence rate in human cancers. Such mutations reduce the ability of the …

Mutations or loss of both alleles of the von Hippel-Lindau (VHL) tumor suppressor gene has
been documented in sporadic renal cell carcinomas and neoplasms that arise in individuals …

The vascular endothelial growth factor (VEGF) receptor FLT-1 has been shown to be involved
in vasculogenesis and angiogenesis. The receptor is characterized by seven Ig-like loops …

Lead optimization of a high‐throughput screening hit led to the rapid identification of
aminopyrimidine ZK 304709, a multitargeted CDK and VEGF‐R inhibitor that displayed a promising …

Polo-like kinase 1 (Plk1) is a key regulator of mitotic progression and cell division in eukaryotes.
It is highly expressed in tumor cells and considered a potential target for cancer therapy. …

Stimulation of NIH3T3 cells with platelet-derived growth factor (PDGF)-BB enhances expression
of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a …

The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells.
DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on …

Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint
function and increased expression of antiapoptotic proteins, which has been directly …

Growth ofsolid tumors and the formation of metas-tases are dependent on the formation. of
new blood vessels. This hypothesis was proposed by Judah Folkman more than 25 years …